Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Pulse Wave Velocities Derived From Cuff Ambulatory Pulse Wave Analysis.

Schwartz JE, Feig PU, Izzo JL Jr.

Hypertension. 2019 Jul;74(1):111-116. doi: 10.1161/HYPERTENSIONAHA.119.12756. Epub 2019 May 28.

PMID:
31132952
2.

Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action.

Shah S, Pitt B, Brater DC, Feig PU, Shen W, Khwaja FS, Wilcox CS.

J Am Heart Assoc. 2017 Oct 5;6(10). pii: e006135. doi: 10.1161/JAHA.117.006135.

3.

Clinical Use of Pulse Wave Analysis: Proceedings From a Symposium Sponsored by North American Artery.

Townsend RR, Black HR, Chirinos JA, Feig PU, Ferdinand KC, Germain M, Rosendorff C, Steigerwalt SP, Stepanek JA.

J Clin Hypertens (Greenwich). 2015 Jul;17(7):503-13. doi: 10.1111/jch.12574. Epub 2015 May 23.

4.

Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension.

Shah S, Hermanowski-Vosatka A, Gibson K, Ruck RA, Jia G, Zhang J, Hwang PM, Ryan NW, Langdon RB, Feig PU.

J Am Soc Hypertens. 2011 May-Jun;5(3):166-76. doi: 10.1016/j.jash.2011.01.009. Epub 2011 Mar 21.

PMID:
21419745
5.

Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome.

Feig PU, Shah S, Hermanowski-Vosatka A, Plotkin D, Springer MS, Donahue S, Thach C, Klein EJ, Lai E, Kaufman KD.

Diabetes Obes Metab. 2011 Jun;13(6):498-504. doi: 10.1111/j.1463-1326.2011.01375.x.

PMID:
21272190
6.

Training the translational scientist.

Jackson RD, Gabriel S, Pariser A, Feig P.

Sci Transl Med. 2010 Dec 22;2(63):63mr2. doi: 10.1126/scitranslmed.3001632.

PMID:
21178132
7.

Single-dose effects of isosorbide mononitrate alone or in combination with losartan on central blood pressure.

Kaufman R, Nunes I, Bolognese JA, Miller DL, Salotti D, McCarthy JM, Smith WB, Herman GA, Feig PU.

J Am Soc Hypertens. 2010 Nov-Dec;4(6):311-8. doi: 10.1016/j.jash.2010.10.004.

PMID:
21130977
8.

Central blood pressure measurements-an opportunity for efficacy and safety in drug development?

Townsend RR, Roman MJ, Najjar SS, Cockcroft JR, Feig PU, Stockbridge NL.

J Am Soc Hypertens. 2010 Sep-Oct;4(5):211-4. doi: 10.1016/j.jash.2010.07.002. Epub 2010 Aug 21.

PMID:
20729159
9.

Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension.

Jones-Burton C, Rubino J, Roy S, Mai Y, Meehan A, Bellet M, Feig P.

J Am Soc Hypertens. 2010 Sep-Oct;4(5):219-26. doi: 10.1016/j.jash.2010.06.006. Epub 2010 Aug 12.

PMID:
20705534
10.

Antihypertensive drug development: current challenges and future opportunities.

Feig PU, Roy S, Cody RJ.

J Am Soc Hypertens. 2010 Jul-Aug;4(4):163-73. doi: 10.1016/j.jash.2010.04.003. Epub 2010 May 27. Review.

PMID:
20537610
11.

Next-generation biomarkers for detecting kidney toxicity.

Bonventre JV, Vaidya VS, Schmouder R, Feig P, Dieterle F.

Nat Biotechnol. 2010 May;28(5):436-40. doi: 10.1038/nbt0510-436. No abstract available.

12.

Fifty years of thiazide diuretic therapy for hypertension.

Moser M, Feig PU.

Arch Intern Med. 2009 Nov 9;169(20):1851-6. doi: 10.1001/archinternmed.2009.342. Review.

PMID:
19901136
14.

Effect on blood pressure control of switching from valsartan monotherapy to losartan/hydrochlorothiazide in Asian patients with hypertension: results of a multicentre open-label trial.

Watanabe LA, Wei M, Sun N, Kim D, Chiang CE, Ke Y, Tseng CD, Coloma R, Vala M, Massaad R, Feig P, Guptha S.

Curr Med Res Opin. 2006 Oct;22(10):1955-64.

PMID:
17022855
15.

Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.

Johnston PS, Feig PU, Coniff RF, Krol A, Kelley DE, Mooradian AD.

Diabetes Care. 1998 Mar;21(3):416-22.

PMID:
9540025
16.

Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.

Johnston PS, Feig PU, Coniff RF, Krol A, Davidson JA, Haffner SM.

Diabetes Care. 1998 Mar;21(3):409-15.

PMID:
9540024
17.

The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.

Segal P, Feig PU, Schernthaner G, Ratzmann KP, Rybka J, Petzinna D, Berlin C.

Diabetes Care. 1997 May;20(5):687-91.

PMID:
9135927
18.

The ABCD (Appropriate Blood Pressure Control in Diabetes) trial. Rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes.

Savage S, Johnson Nagel N, Estacio RO, Feig PU, MacCarthy EP, Lukken NJ, Ziegler R, Schrier RW.

Online J Curr Clin Trials. 1993 Nov 24;Doc No 104:[6250 words; 128 paragraphs].

PMID:
8305994
19.
20.

The efficacy and safety of once-daily nifedipine coat-core in the treatment of mild-to-moderate hypertension. Adalat CC Cooperative Study Group.

Feig PU, Gibson L, Mac Carthy EP, Pettis PP, Schwartz L.

Clin Ther. 1993 Nov-Dec;15(6):963-75. Erratum in: Clin Ther 1994 Jan-Feb;16(1):125.

PMID:
8111816
21.

A comparison of once-daily atenolol and metoprolol using office and ambulatory blood pressure monitoring.

Rutan GH, Feig PU, May S, Kriegman AG, Brady EM.

J Clin Pharmacol. 1993 May;33(5):418-26.

PMID:
8331198
22.

Effectiveness of once-daily monotherapy with a new nifedipine sustained release calcium antagonist.

Carr AA, Bottini PB, Feig P, Prisant LM, Mulligan S, Devane JG, Fisher L, Rhoades RB, MacCarthy EP.

Am J Cardiol. 1992 Apr 30;69(13):28E-32E.

PMID:
1575174
23.

Potassium supplementation attenuates experimental hypertensive renal injury.

Ellis D, Banner B, Janosky JE, Feig PU.

J Am Soc Nephrol. 1992 Apr;2(10):1529-37.

24.
25.
26.

Angiotensin converting enzyme inhibitors: the end of end-stage renal disease?

Feig PU, Rutan GH.

Ann Intern Med. 1989 Sep 15;111(6):451-3. Review. No abstract available.

PMID:
2672924
27.

Lymphocyte membrane sodium-proton exchange in spontaneously hypertensive rats.

Feig PU, D'Occhio MA, Boylan JW.

Hypertension. 1987 Mar;9(3):282-8.

PMID:
3028956
28.

Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation.

Sweeney KR, Chapron DJ, Brandt JL, Gomolin IH, Feig PU, Kramer PA.

Clin Pharmacol Ther. 1986 Nov;40(5):518-24. Erratum in: Clin Pharmacol Ther 1987 Jan;41(1):67.

PMID:
3769383
29.
30.

Erythrocyte membrane transport in hypertensive humans and rats. Effect of sodium depletion and excess.

Feig PU, Mitchell PP, Boylan JW.

Hypertension. 1985 May-Jun;7(3 Pt 1):423-9.

PMID:
3997225
31.

Influence of advanced age on the disposition of acetazolamide.

Chapron DJ, Sweeney KR, Feig PU, Kramer PA.

Br J Clin Pharmacol. 1985 Mar;19(3):363-71.

32.

Aminoglycoside nephrotoxicity: a double blind prospective randomized study of gentamicin and tobramycin.

Feig PU, Mitchell PP, Abrutyn E, Brock SM, Carney WR, Graeber CW, Horak E, Lyons RW, Maher JF.

J Antimicrob Chemother. 1982 Sep;10(3):217-26. No abstract available.

PMID:
6754682
33.

Radiosulfate determination of extracellular fluid volume in morbid obesity.

Karimeddini MK, Feig PU, McAloon M.

Eur J Nucl Med. 1982;7(11):521-2. No abstract available.

PMID:
7173251
34.

Hemodialysis in the treatment of life-threatening hyperphosphatemia.

Feig PU, Hirszel P, Galen MA, Rosenworcel E, Raisz LG.

Clin Exp Dial Apheresis. 1982;6(2-3):105-11. No abstract available.

PMID:
7151322
35.

Internal potassium balance and the control of the plasma potassium concentration.

Sterns RH, Cox M, Feig PU, Singer I.

Medicine (Baltimore). 1981 Sep;60(5):339-54. Review.

PMID:
6268928
36.

The disposition of intravenous potassium in normal man: the role of insulin.

Sterns RH, Guzzo J, Feig PU.

Clin Sci (Lond). 1981 Jul;61(1):23-8.

PMID:
7018811
37.

Hypernatremia and hypertonic syndromes.

Feig PU.

Med Clin North Am. 1981 Mar;65(2):271-90. No abstract available.

PMID:
7230958
38.

Effect of potassium removal during hemodialysis on the plasma potassium concentration.

Feig PU, Shook A, Sterns RH.

Nephron. 1981;27(1):25-30.

PMID:
7219633
39.
40.

Drug therapy in renal failure: dosing guidelines for adults. Part I: Antimicrobial agents, analgesics.

Bennett WM, Muther RS, Parker RA, Feig P, Morrison G, Golper TA, Singer I.

Ann Intern Med. 1980 Jul;93(1):62-89. Review.

PMID:
6994534
41.

An approach to proteinuria.

Rosenworcel E, Feig PU.

Compr Ther. 1979 Sep;5(9):26-31. No abstract available.

PMID:
487738
42.

Disposition of intravenous potassium in anuric man: a kinetic analysis.

Sterns RH, Feig PU, Pring M, Guzzo J, Singer I.

Kidney Int. 1979 Jun;15(6):651-60.

43.

Presence of sodium transport inhibiting factor in dog plasma during volume expansion.

Sterns RH, Singer I, Feig PU.

Experientia. 1979 Feb 15;35(2):222-3.

PMID:
421839
44.

Control of hypertension and reversal of renal failure in scleroderma.

Mitnick PD, Feig PU.

N Engl J Med. 1978 Oct 19;299(16):871-2. No abstract available.

PMID:
692580
45.

Diagnosis of hypotonic states.

Feig PU, Sterns RH.

Ann Intern Med. 1978 May;88(5):717. No abstract available.

PMID:
646272
46.

The hypertonic state.

Feig PU, McCurdy DK.

N Engl J Med. 1977 Dec 29;297(26):1444-54. Review. No abstract available.

PMID:
337143
47.

Guidelines for drug therapy in renal failure.

Bennett WM, Singer I, Golper T, Feig P, Coggins CJ.

Ann Intern Med. 1977 Jun;86(6):754-83.

PMID:
869359
48.

Dependence of the driving force of the sodium pump on rate of transport.

Feig PU, Wetzel GD, Frazier HS.

Am J Physiol. 1977 May;232(5):448-54. doi: 10.1152/ajprenal.1977.232.5.F448.

PMID:
871177
49.

Vasculitis with urticaria, hypocomplementemia, and multiple system involvement.

Feig PU, Soter NA, Yager HM, Caplan L, Rosen S.

JAMA. 1976 Nov 1;236(18):2065-8.

PMID:
989789

Supplemental Content

Support Center